InBrain Pharma, a Lille, France-based clinical stage biotechnology company which specializes in therapeutic solution development against neurodegenerative diseases, raised €1.8M in funding.
Backers were not disclosed.
The company intends to use the funds to support its PERCEPAR project (PERfusion CErébrale de dopamine, a therapeutic innovation for PARkinson’s patients).
Founded in 2018, InBrain Pharma is a biopharmaceutical company that leverages personalized medicine in neurology, titrating dopamine in the brain by circadian intracerebroventricular infusion to treat patients with advanced-stage Parkinson’s disease. It holds a global license from SATT Nord to exploit the patents covering this therapeutic approach for Parkinson’s disease.
This innovation is based on the research conducted by Professors David Devos and Caroline Moreau within their academic team at the University of Lille, Lille Neuroscience & Cognition UMR-S 1172 INSERM, and Lille University Hospital.
FinSMEs
12/05/2025